| BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1 SJ Hogg, SJ Vervoort, S Deswal, CJ Ott, J Li, LA Cluse, PA Beavis, ... Cell reports 18 (9), 2162-2174, 2017 | 295 | 2017 |
| Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy M Chesi, GM Matthews, VM Garbitt, SE Palmer, J Shortt, M Lefebure, ... Blood, The Journal of the American Society of Hematology 120 (2), 376-385, 2012 | 246 | 2012 |
| Oncogenes in cell survival and cell death J Shortt, RW Johnstone Cold Spring Harbor perspectives in biology 4 (12), a009829, 2012 | 186 | 2012 |
| CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo GP Gregory, SJ Hogg, LM Kats, E Vidacs, AJ Baker, O Gilan, M Lefebure, ... Leukemia 29 (6), 1437-1441, 2015 | 158 | 2015 |
| An intact immune system is required for the anticancer activities of histone deacetylase inhibitors AC West, SR Mattarollo, J Shortt, LA Cluse, AJ Christiansen, MJ Smyth, ... Cancer research 73 (24), 7265-7276, 2013 | 149 | 2013 |
| ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura J Shortt, DH Oh, SS Opat New England Journal of Medicine 368 (1), 90-92, 2013 | 143 | 2013 |
| Differentiation therapy for the treatment of t (8; 21) acute myeloid leukemia using histone deacetylase inhibitors M Bots, I Verbrugge, BP Martin, JM Salmon, M Ghisi, A Baker, K Stanley, ... Blood, The Journal of the American Society of Hematology 123 (9), 1341-1352, 2014 | 142 | 2014 |
| Combination therapy targeting ribosome biogenesis and mRNA translation synergistically extends survival in MYC-driven lymphoma JR Devlin, KM Hannan, N Hein, C Cullinane, E Kusnadi, PY Ng, ... Cancer discovery 6 (1), 59-70, 2016 | 135 | 2016 |
| Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS … U Platzbecker, MG Della Porta, V Santini, AM Zeidan, RS Komrokji, ... The Lancet 402 (10399), 373-385, 2023 | 126 | 2023 |
| Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy J Shortt, AK Hsu, RW Johnstone Oncogene 32 (36), 4191-4202, 2013 | 125 | 2013 |
| The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia A Baker, GP Gregory, I Verbrugge, L Kats, JJ Hilton, E Vidacs, EM Lee, ... Cancer research 76 (5), 1158-1169, 2016 | 122 | 2016 |
| Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition SJ Hogg, O Motorna, LA Cluse, TM Johanson, HD Coughlan, R Raviram, ... Molecular cell 81 (10), 2183-2200. e13, 2021 | 100 | 2021 |
| A chemical probe toolbox for dissecting the cancer epigenome J Shortt, CJ Ott, RW Johnstone, JE Bradner Nature Reviews Cancer 17 (3), 160-183, 2017 | 99 | 2017 |
| NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma SR Mattarollo, AC West, K Steegh, H Duret, C Paget, B Martin, ... Blood, The Journal of the American Society of Hematology 120 (15), 3019-3029, 2012 | 89 | 2012 |
| Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas J Shortt, BP Martin, A Newbold, KM Hannan, JR Devlin, AJ Baker, R Ralli, ... Blood, The Journal of the American Society of Hematology 121 (15), 2964-2974, 2013 | 87 | 2013 |
| Manipulation of B-cell responses with histone deacetylase inhibitors M Waibel, AJ Christiansen, ML Hibbs, J Shortt, SA Jones, I Simpson, ... Nature communications 6 (1), 6838, 2015 | 83 | 2015 |
| A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies DC Phillips, S Jin, GP Gregory, Q Zhang, J Xue, X Zhao, J Chen, Y Tong, ... Leukemia 34 (6), 1646-1657, 2020 | 80 | 2020 |
| Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand LC Fox, SJ Cohney, JY Kausman, J Shortt, PD Hughes, EM Wood, ... Internal medicine journal 48 (6), 624-636, 2018 | 80 | 2018 |
| Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma J Shortt, A Spencer Bone marrow transplantation 38 (6), 433-436, 2006 | 77 | 2006 |
| BET inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members SJ Hogg, A Newbold, SJ Vervoort, LA Cluse, BP Martin, GP Gregory, ... Molecular cancer therapeutics 15 (9), 2030-2041, 2016 | 76 | 2016 |
Stephen OpatMonash UniversityEmail verificata su monash.edu